Drug class in one race
CDK4 drugs for HR+/HER2- Metastatic Breast Cancer
5 tracked CDK4 drugs in the HR+/HER2- Metastatic Breast Cancer race. The class explanation lives on the CDK4 page; the full indication pipeline across every mechanism is on the HR+/HER2- Metastatic Breast Cancer page.
2 Phase 32 Phase 21 Phase 1/2
Head-to-head evidence: Atirmociclib vs AVZO-023 · Atirmociclib vs BGB-43395 · Atirmociclib vs HRS-6209 · Atirmociclib vs SHR-6209